Akari Therapeutics (CLA1) Financial Statements
Akari Therapeutics Financial Overview
Akari Therapeutics's market cap is currently $12.87M. The company's EPS TTM is $-1600.00; its P/E ratio is -0.01; Akari Therapeutics has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Operating Income | $ -17.27M | $ -21.64M | $ -16.81M | $ -23.09M | $ -17.21M |
| EBITDA | $ -17.35M | $ -19.53M | $ -10.00M | $ -17.74M | $ -17.42M |
| Net Income | $ -17.30M | $ -19.79M | $ -10.01M | $ -17.75M | $ -17.42M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 5.20M | $ 2.60M | $ 3.85M | $ 13.25M | $ 9.36M |
| Total Assets | $ 47.89M | $ 50.56M | $ 4.36M | $ 13.83M | $ 11.65M |
| Total Debt | $ 754.00K | $ 3.26M | $ 0.00 | $ 0.00 | $ 0.00 |
| Net Debt | $ -4.45M | $ 661.00K | $ -3.85M | $ -13.25M | $ -9.36M |
| Total Liabilities | $ 19.56M | $ 28.33M | $ 4.58M | $ 12.04M | $ 6.09M |
| Stockholders' Equity | $ 28.33M | $ 22.23M | $ -229.00K | $ 1.79M | $ 5.55M |
| Cash Flow | |||||
| Free Cash Flow | $ -10.57M | $ -12.55M | $ -16.43M | $ -21.50M | $ -18.85M |
| Operating Cash Flow | $ -10.57M | $ -12.55M | $ -16.43M | $ -21.50M | $ -18.85M |
| Investing Cash Flow | $ 0.00 | $ 382.00K | $ 0.00 | $ 0.00 | $ 0.00 |
| Financing Cash Flow | $ 13.17M | $ 10.99M | $ 7.02M | $ 25.29M | $ 14.29M |
Currency in USD